According to filings with the U.S. Securities and Exchange Commission, Pheast Therapeutics, Inc. is raising up to $39,999,993.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Pheast Therapeutics, Inc.
The foundational research that became Pheast Therapeutics took place in the Weissman Lab, the heart of the Stanford University Institute for Stem Cell Biology and Regenerative Medicine, which Dr. Irv Weissman founded and directed. This is where our cofounders met and trained in pursuit of scientific discovery. Now, at Pheast, we continue the work of shepherding those discoveries through the clinic and into patient therapies.

To learn more about Pheast Therapeutics, Inc., visit https://www.pheast.com/
Pheast Therapeutics, Inc. Linkedin Page: https://www.linkedin.com/company/pheast-therapeutics/

Contact:
Roy Maute, Chief Executive Officer
650-374-2223
https://www.linkedin.com/in/roy-maute-2b31b975/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.